208 results on '"Andronis, Lazaros"'
Search Results
2. Health-related quality of life at 5 years of age for children born very preterm with congenital anomalies: a multi-national cohort study
3. Economic Considerations in Designs and Modifications of Multiarm, Multistage Adaptive and Adaptive Platform Randomized Controlled Trials: A Systematic Literature Review
4. Cost-Effectiveness of Intrathecal Drug Delivery
5. Health-related quality of life of children born very preterm: a multinational European cohort study
6. Views, obstacles, and uncertainties around the inclusion of children and young people's time in economic evaluations: Findings from an international survey of health economists
7. Bio-impedance spectroscopy added to a fluid management protocol does not improve preservation of residual kidney function in incident hemodialysis patients in a randomized controlled trial
8. Economic costs at age five associated with very preterm birth: multinational European cohort study
9. High Healthcare Use at Age 5 Years in a European Cohort of Children Born Very Preterm
10. Health-related quality of life at 5 years of age for children born very preterm with congenital anomalies: a multi-national cohort study
11. Cardiac prehabilitation, rehabilitation and education in first-time atrial fibrillation (AF) ablation (CREED AF): Study protocol for a randomised controlled trial.
12. Variation in follow-up for children born very preterm in Europe
13. Measuring, valuing and including forgone childhood education and leisure time costs in economic evaluation: Methods, challenges and the way forward
14. Analytic approaches for informing research funding decisions : an exploration of their role and value using case studies of cancer clinical trials
15. Is the Venner-PneuX Endotracheal Tube System a Cost-Effective Option for Post Cardiac Surgery Care?
16. The PLANES study: a protocol for a randomised controlled feasibility study of the placental growth factor (PlGF) blood test-informed care versus standard care alone for women with a small for gestational age fetus at or after 32 + 0 weeks’ gestation
17. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results
18. Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation
19. Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
20. Variation in follow-up for children born very preterm in Europe.
21. Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review
22. Cost-Effectiveness of Non-Invasive and Non-Pharmacological Interventions for Low Back Pain: a Systematic Literature Review
23. Impact of updated trial data on the cost-effectiveness of percutaneous mitral repair
24. Health-related quality of life of children born very preterm : a multinational European cohort study
25. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study
26. B06 What is the best location for a defibrillator to improve OHCA coverage?
27. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial
28. REducing Colonoscopies in patients without significant bowEl DiseasE: the RECEDE Study - protocol for a prospective diagnostic accuracy study
29. Procedural and 12-month in-hospital costs of primary infra-popliteal bypass surgery, infrapopliteal best endovascular treatment, and major lower limb amputation for chronic limb threatening ischemia
30. Quality of life in painful diabetic neuropathy patients following treatment with spinal cord stimulation: 10 June – 056.
31. Follow-up after very preterm birth in Europe
32. Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective
33. Are acceptance and mindfulness‐based interventions ‘value for money’? Evidence from a systematic literature review
34. Validation of the Bluebelle Wound Healing questionnaire (WHQ) for assessment of surgical site infection in primary surgical wounds after hospital discharge
35. Additional file 8: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
36. Additional file 1: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
37. Additional file 7: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
38. Additional file 4: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
39. Additional file 3: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
40. Additional file 2: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
41. Additional file 5: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
42. Additional file 6: of Comparative survival benefit of currently licensed second or third line treatments for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) negative advanced or metastatic non-small cell lung cancer: a systematic review and secondary analysis of trials
43. Three wound-dressing strategies to reduce surgical site infection after abdominal surgery: the Bluebelle feasibility study and pilot RCT
44. Participants' preference for type of leaflet used to feed back the results of a randomised trial: a survey
45. Developing outcome measures assessing wound management and patient experience: a mixed methods study
46. Micronutrient deficiencies and health-related quality of life: the case of children with vitamin D deficiency
47. Micronutrient deficiencies and health-related quality of life: the case of children with vitamin D deficiency.
48. Are acceptance and mindfulness‐based interventions ‘value for money’? Evidence from a systematic literature review
49. Additional file 1: of BAlloon versus Stenting in severe Ischaemia of the Leg-3 (BASIL-3): study protocol for a randomised controlled trial
50. Cost-Effectiveness of Treatments for the Management of Bone Metastases: A Systematic Literature Review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.